The study to identify risk of botulinum toxin treatment failure due to the antibody
Phase 4
Recruiting
- Conditions
- Healthy human volunteers, Patient with history of botulinum toxin treatment failure.Enzyme-Linked Immunosorbent Assay, Botulinum Toxins, Immunoglobulins, Antibodies
- Registration Number
- TCTR20220525004
- Lead Sponsor
- Merz Healthcare (Thailand) Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Male or Female with history of botulinum toxin treatment failure
No history of chronic disease
Exclusion Criteria
Subject who using immunosuppressive medication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody level At the beginning of the study ng/ml
- Secondary Outcome Measures
Name Time Method History of botulinum toxin usage At the beginning of the study Patient reported outcome using a questionnaire interview